CHF 0.84
(-6.44%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 9.43 Million CHF | -73.25% |
2022 | 15.53 Million CHF | 57.32% |
2021 | 9.87 Million CHF | 30.99% |
2020 | 7.54 Million CHF | -34.97% |
2019 | 11.59 Million CHF | 29.82% |
2018 | 8.93 Million CHF | 30.47% |
2017 | 6.84 Million CHF | -28.5% |
2016 | 9.57 Million CHF | -28.34% |
2015 | 13.36 Million CHF | 24.38% |
2014 | 10.74 Million CHF | 23.41% |
2013 | 8.7 Million CHF | 24.12% |
2012 | 7.01 Million CHF | -36.69% |
2011 | 11.08 Million CHF | -40.52% |
2010 | 18.62 Million CHF | -1.58% |
2009 | 18.92 Million CHF | 4359.59% |
2008 | 424.4 Thousand CHF | 157.98% |
2007 | 164.51 Thousand CHF | -39.86% |
2006 | 273.56 Thousand CHF | 0.0% |
2005 | - CHF | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - CHF | 0.0% |
2023 Q2 | 4.45 Million CHF | 0.0% |
2023 Q4 | -295.9 Thousand CHF | 0.0% |
2023 FY | 4.15 Million CHF | -73.25% |
2022 Q2 | 8.13 Million CHF | 0.0% |
2022 Q4 | 7.4 Million CHF | 0.0% |
2022 FY | 15.53 Million CHF | 57.32% |
2021 FY | 9.87 Million CHF | 30.99% |
2021 Q4 | 3.5 Million CHF | 0.0% |
2021 Q2 | 6.37 Million CHF | 0.0% |
2020 FY | 7.54 Million CHF | -34.97% |
2020 Q2 | 3.96 Million CHF | 0.0% |
2020 Q4 | 3.57 Million CHF | 0.0% |
2019 FY | 11.59 Million CHF | 29.82% |
2019 Q2 | 6.36 Million CHF | 0.0% |
2019 Q4 | 5.22 Million CHF | 0.0% |
2018 FY | 8.93 Million CHF | 30.47% |
2018 Q2 | 3.8 Million CHF | 0.0% |
2018 Q4 | 5.12 Million CHF | 0.0% |
2017 Q2 | 3.61 Million CHF | 0.0% |
2017 FY | 6.84 Million CHF | -28.5% |
2017 Q4 | 3.22 Million CHF | 0.0% |
2016 FY | 9.57 Million CHF | -28.34% |
2016 Q2 | 3.67 Million CHF | 0.0% |
2016 Q4 | 5.89 Million CHF | 0.0% |
2015 FY | 13.36 Million CHF | 24.38% |
2015 Q4 | 5.08 Million CHF | 0.0% |
2015 Q2 | 8.27 Million CHF | 0.0% |
2014 Q4 | 5.75 Million CHF | 0.0% |
2014 FY | 10.74 Million CHF | 23.41% |
2014 Q2 | 4.98 Million CHF | 0.0% |
2013 Q4 | 4.72 Million CHF | 0.0% |
2013 FY | 8.7 Million CHF | 24.12% |
2013 Q2 | 3.97 Million CHF | 0.0% |
2012 FY | 7.01 Million CHF | -36.69% |
2012 Q4 | 2.17 Million CHF | 24.12% |
2012 Q1 | 1.75 Million CHF | 0.0% |
2012 Q2 | 1.75 Million CHF | 0.0% |
2012 Q3 | 1.75 Million CHF | 0.0% |
2011 Q1 | 2.77 Million CHF | 0.0% |
2011 Q2 | 2.77 Million CHF | 0.0% |
2011 Q3 | 2.77 Million CHF | 0.0% |
2011 Q4 | 1.75 Million CHF | -36.69% |
2011 FY | 11.08 Million CHF | -40.52% |
2010 FY | 18.62 Million CHF | -1.58% |
2010 Q4 | 2.77 Million CHF | -40.52% |
2010 Q3 | 4.65 Million CHF | 0.0% |
2010 Q2 | 4.65 Million CHF | 0.0% |
2010 Q1 | 4.65 Million CHF | 0.0% |
2009 Q2 | 4.73 Million CHF | 0.0% |
2009 Q4 | 4.65 Million CHF | -1.58% |
2009 Q3 | 4.73 Million CHF | 0.0% |
2009 FY | 18.92 Million CHF | 4359.59% |
2009 Q1 | 4.73 Million CHF | 0.0% |
2008 Q1 | 106.1 Thousand CHF | 0.0% |
2008 Q4 | 4.73 Million CHF | 4359.59% |
2008 Q3 | 106.1 Thousand CHF | 0.0% |
2008 FY | 424.4 Thousand CHF | 157.98% |
2008 Q2 | 106.1 Thousand CHF | 0.0% |
2007 Q3 | 41.12 Thousand CHF | 0.0% |
2007 Q1 | 41.12 Thousand CHF | 0.0% |
2007 Q4 | 106.1 Thousand CHF | 157.98% |
2007 FY | 164.51 Thousand CHF | -39.86% |
2007 Q2 | 41.12 Thousand CHF | 0.0% |
2006 Q3 | 68.39 Thousand CHF | 0.0% |
2006 Q2 | 68.39 Thousand CHF | 0.0% |
2006 Q1 | 68.39 Thousand CHF | 0.0% |
2006 FY | 273.56 Thousand CHF | 0.0% |
2006 Q4 | 41.12 Thousand CHF | -39.86% |
2005 FY | - CHF | 0.0% |
2005 Q4 | 68.39 Thousand CHF | 0.0% |
2005 Q3 | - CHF | 0.0% |
2005 Q2 | - CHF | 0.0% |
2005 Q1 | - CHF | 0.0% |
2004 Q4 | - CHF | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Addex Therapeutics Ltd | 1.61 Million CHF | -483.593% |
BB Biotech AG | -199.56 Million CHF | 104.729% |
Basilea Pharmaceutica AG | 157.63 Million CHF | 94.013% |
Idorsia Ltd | 152.38 Million CHF | 93.807% |
Kuros Biosciences AG | 33.56 Million CHF | 71.881% |
Molecular Partners AG | 7.03 Million CHF | -34.098% |
Relief Therapeutics Holding AG | 6.03 Million CHF | -56.436% |
Santhera Pharmaceuticals Holding AG | 103.41 Million CHF | 90.874% |